Gammaherpesvirus infection of human neuronal cells

mBio

Volumn 6, Issue 6, 2015, Pages

  Jha, Hem Chandra ^a   Mehta, Devan ^a   Lu, Jie ^a   El Naccache, Darine ^a   Shukla, Sanket K ^a   Kovacsics, Colleen ^b   Kolson, Dennis ^b   Robertson, Erle S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; IMMEDIATE EARLY PROTEIN BZLF1; ACICLOVIR; ANTIVIRUS AGENT; GREEN FLUORESCENT PROTEIN;

ARTICLE; BRAIN DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA VIRUS INFECTION; EPSTEIN BARR VIRUS; FETUS; GAMMAHERPESVIRINAE; GENE EXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IMMUNOFLUORESCENCE; IN VITRO STUDY; INFECTION; MICROSCOPY; NERVE CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REPLICATION; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOHISTOCHEMISTRY; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; REPORTER GENE; STAINING; VIROLOGY;

ACYCLOVIR; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; MICROSCOPY, FLUORESCENCE; NEURONS; STAINING AND LABELING; VIRUS REPLICATION;

EID: 84952836849     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01844-15     Document Type: Article

References (72)

1. Tao Q, Young LS, Woodman CB, Murray PG. 2006. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 11:2672-2713. http:// dx.doi.org/10.2741/2000.
2. Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, Aoki S, Minami M, Uozaki H, Fukayama M, Ohtomo K. 2009. Spectrum of Epstein-Barr virus-related diseases: a pictorial review. Jpn J Radiol 27: 4-19. http://dx.doi.org/10.1007/s11604-008-0291-2.
3. Küppers R. 2003. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3:801-812. http://dx.doi.org/ 10.1038/nri1201.
4. Rickinson AB, Kieff E. 2001. Epstein-Barr virus. In Knipe DM, Howley GD, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology. Lippincott Williams & Wilkins: Philadelphia, PA.
5. Sixbey JW, Davis DS, Young LS, Hutt-Fletcher L, Tedder TF, Rickinson AB. 1987. Human epithelial cell expression of an Epstein-Barr virus receptor. J Gen Virol 68:805-811. http://dx.doi.org/10.1099/0022-1317-68-3-805.
6. Baumforth KR, Young LS, Flavell KJ, Constandinou C, Murray PG. 1999. The Epstein-Barr virus and its association with human cancers. Mol Pathol 52:307-322. http://dx.doi.org/10.1136/mp.52.6.307.
7. Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, Wahl R, Sands J, Gottman D, Katz BZ, Sklar J. 1988. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med 318:733-741. http://dx.doi.org/10.1056/ NEJM198803243181203.
8. Amon W, Farrell PJ. 2005. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 15:149-156. http://dx.doi.org/10.1002/rmv.456.
9. Ebell MH. 2004. Epstein-Barr virus infectious mononucleosis. Am Fam Physician 70:1279-1287.
10. Thompson MP, Kurzrock R. 2004. Epstein-Barr virus and cancer. Clin Cancer Res 10:803-821. http://dx.doi.org/10.1158/1078-0432.CCR-0670-3.
11. Brady G, Macarthur GJ, Farrell PJ. 2008. Epstein-Barr virus and Burkitt lymphoma. Postgrad Med J 84:372-377. http://dx.doi.org/10.1136/ jcp.2007.047977.
12. Takada K. 2001. Role of Epstein-Barr virus in Burkitt's lymphoma. Curr Top Microbiol Immunol 258:141-151. http://dx.doi.org/10.1007/978-3-642-56515-1_9.
13. Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS, Chang Y. 2000. Differential viral protein expression in Kaposi's sarcomaassociated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 156: 743-749. http://dx.doi.org/10.1016/S0002-9440(10)64940-1.
14. Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS, Chang Y. 2000. Differential viral protein expression in Kaposi's sarcomaassociated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 156: 743-749. http://dx.doi.org/10.1016/S0002-9440(10)64940-1.
15. Janz A, Oezel M, Kurzeder C, Mautner J, Pich D, Kost M, Hammerschmidt W, Delecluse H-. 2000. Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol 74:10142-10152. http://dx.doi.org/10.1128/ JVI.74.21.10142-10152.2000.
16. Tanner J, Weis J, Fearon D, Whang Y, Kieff E. 1987. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50:203-213. http://dx.doi.org/ 10.1016/0092-8674(87)90216-9.
17. Xiao J, Palefsky JM, Herrera R, Berline J, Tugizov SM. 2009. EBV BMRF-2 facilitates cell-to-cell spread of virus within polarized oral epithelial cells. Virology 388:335-343. http://dx.doi.org/10.1016/ j.virol.2009.03.030.
18. Tugizov SM, Berline JW, Palefsky JM. 2003. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 9:307-314. http://dx.doi.org/10.1038/nm830.
19. Bajaj BG, Murakami M, Robertson ES. 2007. Molecular biology of EBV in relationship to AIDS-associated oncogenesis. Cancer Treat Res 133: 141-162. http://dx.doi.org/10.1007/978-0-387-46816-7_5.
20. Middeldorp JM, Brink AATP, van den Brule AJC, Meijer CJLM. 2003. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBVassociated proliferative disorders. Crit Rev Oncol Hematol 45:1-36. http://dx.doi.org/10.1016/S1040-8428(02)00078-1.
21. Sivachandran N, Wang X, Frappier L. 2012. Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection. J Virol 86:6146-6158. http://dx.doi.org/10.1128/JVI.00013-12.
22. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande J, Weiss RA, Alitalo K, Boshoff C. 1999. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 96:4546-4551. http://dx.doi.org/ 10.1073/pnas.96.8.4546.
23. Young LS, Murray PG. 2003. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22:5108-5121. http://dx.doi.org/ 10.1038/sj.onc.1206556.
24. Cesarman E. 2011. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett 305:163-174. http:// dx.doi.org/10.1016/j.canlet.2011.03.003.
25. Neri A, BarrigabF, Inghirami G, Knowles DM, Neequaye J, Magrath IT, Dalla-Favera R. 1991. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 77:1092-1095.
26. Lacoste V. 2004. Kaposi's sarcoma-associated herpesvirus immediate early gene activity. Front Biosci 9:2245-2272. http://dx.doi.org/10.2741/ 1394.
27. Cordier-Bussat M, Billaud M, Calender A, Lenoir GM. 1993. Epstein-Barr virus (EBV) nuclear-antigen-2-induced up-regulation of CD21 and CD23 molecules is dependent on a permissive cellular context. Int J Cancer 53:153-160. http://dx.doi.org/10.1002/ijc.2910530128.
28. Fang C, Huang S, Wu C, Hsu H, Chou S, Tsai C, Chang Y, Takada K, Chen J. 2012. The synergistic effect of chemical carcinogens enhances Epstein-Barr virus reactivation and tumor progression of nasopharyngeal carcinoma cells. PLoS One 7:e44810. http://dx.doi.org/10.1371/ journal.pone.0044810.
29. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S. 2002. The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol 76:12503-12512. http://dx.doi.org/10.1128/JVI.76.24.12503-12512.2002.
30. MacMahon B. 1966. Epidemiology of Hodgkin's disease. Cancer Res 26: 1189-1201.
31. Carbone I, Lazzarotto T, Ianni M, Porcellini E, Forti P, Masliah E, Gabrielli L, Licastro F. 2014. Herpesvirus in Alzheimer's disease: relation to progression of the disease. Neurobiol Aging 35:122-129. http:// dx.doi.org/10.1016/j.neurobiolaging.2013.06.024.
32. Lovett-Racke AE, Racke MK. 2006. Epstein-Barr virus and multiple sclerosis. Arch Neurol 63:810-811. http://dx.doi.org/10.1001/ archneur.63.6.810.
33. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. 2006. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 63:839-844. http://dx.doi.org/10.1001/archneur.63.6.noc50328.
34. Munger K, Levin L, O'Reilly E, Falk K, Ascherio A. 2011. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 17: 1185-1193. http://dx.doi.org/10.1177/1352458511408991.
35. Kleines M, Schiefer J, Stienen A, Blaum M, Ritter K, Häusler M. 2011. Expanding the spectrum of neurological disease associated with Epstein-Barr virus activity. Eur J Clin Microbiol Infect Dis 30:1561-1569. http:// dx.doi.org/10.1007/s10096-011-1261-7.
36. Masajtis-Zagajewska A. 2012. Guillain-Barre syndrome in the course of EBV infection after kidney transplantation-a case report. Ann Transplant 17:133-137. http://dx.doi.org/10.12659/AOT.883468.
37. McCarthy CL, McColgan P, Martin P. 2012. Acute cerebellar ataxia due to Epstein-Barr virus. Pract Neurol 12:238-240. http://dx.doi.org/ 10.1136/practneurol-2011-000115.
38. Robinson TJ, Glenn MS, Temple RW, Wyatt D, Connolly JH. 1980. Encephalitis and cerebellar ataxia associated with Epstein-Barr virus infections. Ulster Med J 49:158-164.
39. Rubin DI, Daube JR. 1999. Subacute sensory neuropathy associated with Epstein-Barr virus. Muscle Nerve 22:1607-1610. http://dx.doi.org/10.1002/ (SICI)1097-4598(199911)22:11_1607::AID-MUS21_3.0.CO;2-J.
40. Gavin C, Langan Y, Hutchinson M. 1997. Cranial and peripheral neuropathy due to Epstein-Barr virus infection. Postgrad Med J 73:419-420. http://dx.doi.org/10.1136/pgmj.73.861.419.
41. Wang J, Ozzard A, Nathan M, Atkins M, Nelson M, Gazzard B, Bower M. 2007. The significance of Epstein-Barr virus detected in the cerebro-spinal fluid of people with HIV infection. HIV Med 8:306-311. http:// dx.doi.org/10.1111/j.1468-1293.2007.00475.x.
42. Weinberg A, Li S, Palmer M, Tyler KL. 2002. Quantitative CSF PCR in Epstein-Barr virus infections of the central nervous system. Ann Neurol 52:543-548. http://dx.doi.org/10.1002/ana.10321.
43. Pender MP. 2011. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 17:351-367. http:// dx.doi.org/10.1177/1073858410381531.
44. Fraser K. 1979. Increased tendency to spontaneous in vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet ii:175-176. http://dx.doi.org/10.1016/S0140-6736(79)90643-3.
45. Sumaya CV, Myers LW, Ellison GW. 1980. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol 37:94-96. http://dx.doi.org/10.1001/ archneur.1980.00500510052009.
46. Pender MP. 2011. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 17:351-367. http:// dx.doi.org/10.1177/1073858410381531.
47. Ascherio A. 2008. Epstein-Barr virus in the development of multiple sclerosis. Expert Rev Neurother 8:331-333. http://dx.doi.org/10.1586/ 14737175.8.3.331.
48. Ascherio A, Munch M. 2000. Epstein-Barr virus and multiple sclerosis. Epidemiology 11:220-224. http://dx.doi.org/10.1097/00001648-200003000-00023.
49. Ascherio A, Munger K. 2008. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 28:17-28. http://dx.doi.org/ 10.1055/s-2007-1019126.
50. Levin LI. 2003. Multiple sclerosis and Epstein-Barr virus. JAMA 289: 1533-1536. http://dx.doi.org/10.1001/jama.289.12.1533.
51. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F. 2007. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204:2899-2912. http://dx.doi.org/10.1084/jem.20071030.
52. Halder S, Murakami M, Verma SC, Kumar P, Yi F, Robertson ES. 2009. Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One 4:e7214. http://dx.doi.org/10.1371/ journal.pone.0007214.
53. Datta AK, Colby BM, Shaw JE, Pagano JS. 1980. Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci U S A 77:5163-5166. http://dx.doi.org/10.1073/pnas.77.9.5163.
54. Lycke J, Svennerholm B, Hjelmquist E, Frisn L, Badr G, Andersson M, Vahlne A, Andersen O. 1996. Acyclovir treatment of relapsing-remitting multiple sclerosis.Arandomized, placebo-controlled, double-blind study. J Neurol 243:214-224. http://dx.doi.org/10.1007/BF00868517.
55. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F. 2007. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204:2899-2912. http://dx.doi.org/10.1084/jem.20071030.
56. Biedler JL, Helson L, Spengler BA. 1973. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33:2643-2652.
57. Ross RA, Spengler BA, Biedler JL. 1983. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 71:741-747.
58. Andrews PW, Damjanov I, Simon D, Banting GS, Carlin C, Dracopoli NC, Føgh J. 1984. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line tera-2. Differentiation in vivo and in vitro. Lab Invest 50:147-162.
59. Pleasure SJ, Lee VM. 1993. NTera 2 cells: a human cell line which displays characteristics expected of a human committed neuronal progenitor cell. J Neurosci Res 35:585-602. http://dx.doi.org/10.1002/jnr.490350603.
60. Napoli A, Obeid I. 18 August 2015. Comparative analysis of human and rodent brain primary neuronal culture spontaneous activity using microelectrode array technology. J Cell Biochem. http://dx.doi.org/10.1002/ jcb.25312.
61. Nuebling C, Buck M, Boos H, Deimling AV, Mueller-Lantzsch N. 1992. Expression of Epstein-Barr virus membrane antigen gp350/220 in E. coli and in insect cells. Virology 191:443-447. http://dx.doi.org/10.1016/0042-6822(92)90207-6.
62. Soltani MH, Soltani MH, Pichardo R, Song Z, Sangha N, Camacho F, Satyamoorthy K, Sangueza OP, Setaluri V. 2005. Microtubuleassociated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am J Pathol 166:1841-1850. http:// dx.doi.org/10.1016/S0002-9440(10)62493-5.
63. Chen W, Sulcove J, Frank I, Jaffer S, Ozdener H, Kolson DL. 2002. Development of a human neuronal cell model for human immunodeficiency virus (HIV)-infected macrophage-induced neurotoxicity: apoptosis induced by HIV type 1 primary isolates and evidence for involvement of the Bcl-2/Bcl-xL-sensitive intrinsic apoptosis pathway. J Virol 76: 9407-9419. http://dx.doi.org/10.1128/JVI.76.18.9407-9419.2002.
64. Martelius T, Lappalainen M, Palomäki M, Anttila V. 2011. Clinical characteristics of patients with Epstein-Barr virus in cerebrospinal fluid. BMC Infect Dis 11:281. http://dx.doi.org/10.1186/1471-2334-11-281.
65. Jha HC, Lu J, Verma SC, Banerjee S, Mehta D, Robertson ES. 2014. Kaposi's sarcoma-associated herpesvirus genome programming during the early stages of primary infection of peripheral blood mononuclear cells. mBio 5:e02261-14. http://dx.doi.org/10.1128/mBio.02261-14.
66. Brulois KF, Chang H, Lee AS-Y, Ensser A, Wong L-Y, Toth Z, Lee SH, Lee H-R, Myoung J, Ganem D, Oh T-K, Kim JF, Gao S-J, Jung JU. 2012. Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome clone. J Virol 86:9708-9720. http://dx.doi.org/10.1128/JVI.01019-12.
67. Jha HC, Lu J, Saha A, Cai Q, Banerjee S, Prasad MAJ, Robertson ES. 2013. EBNA3C-mediated regulation of aurora kinase B contributes to Epstein-Barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases. J Virol 87:12121-12138. http://dx.doi.org/10.1128/JVI.02379-13.
68. Jha HC, Upadhyay SK, Aj MP, Lu J, Cai Q, Saha A, Robertson ES. 2013. H2AX phosphorylation is important for LANA-mediated Kaposi's sarcoma-associated herpesvirus episome persistence. J Virol 87: 5255-5269. http://dx.doi.org/10.1128/JVI.03575-12.
69. Gordon J, Amini S, White MK. 2013. General overview of neuronal cell culture. Methods Mol Biol 1078:1-8. http://dx.doi.org/10.1007/978-1-62703-640-5_1.
70. Myoung J, Ganem D. 2011. Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells. J Clin Invest 121:1130-1140. http://dx.doi.org/10.1172/JCI43755.
71. Lu J, Verma SC, Cai Q, Robertson ES. 2011. The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi's sarcomaassociated herpesvirus latency during primary infection. J Virol 85: 6148-6161. http://dx.doi.org/10.1128/JVI.02608-10.
72. Jha HC, Aj MP, Saha A, Banerjee S, Lu J, Robertson ES. 2014. Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression. J Virol 88:3776-3788. http://dx.doi.org/10.1128/JVI.03568-13.